Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
NKTR 
Nektar Therapeutics (NKTR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: NKTR (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -63.59% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 149.18M USD | Price to earnings Ratio - | 1Y Target Price 4.75 |
Price to earnings Ratio - | 1Y Target Price 4.75 | ||
Volume (30-day avg) 2083981 | Beta 0.66 | 52 Weeks Range 0.65 - 1.93 | Updated Date 03/27/2025 |
52 Weeks Range 0.65 - 1.93 | Updated Date 03/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.58 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-03 | When Before Market | Estimate -0.195 | Actual -0.15 |
Profitability
Profit Margin -120.86% | Operating Margin (TTM) -84.6% |
Management Effectiveness
Return on Assets (TTM) -23.14% | Return on Equity (TTM) -124.1% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -11632702 | Price to Sales(TTM) 1.52 |
Enterprise Value -11632702 | Price to Sales(TTM) 1.52 | ||
Enterprise Value to Revenue 0.78 | Enterprise Value to EBITDA -6.5 | Shares Outstanding 186104000 | Shares Floating 173772364 |
Shares Outstanding 186104000 | Shares Floating 173772364 | ||
Percent Insiders 1.26 | Percent Institutions 71.87 |
Analyst Ratings
Rating 3.62 | Target Price 4.56 | Buy 2 | Strong Buy 2 |
Buy 2 | Strong Buy 2 | ||
Hold 3 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Nektar Therapeutics
Company Overview
History and Background
Nektar Therapeutics was founded in 1990. It initially focused on drug delivery technologies, evolving into a biopharmaceutical company developing its own pipeline of drug candidates.
Core Business Areas
- Drug Discovery and Development: Focuses on discovering and developing novel drug candidates across various therapeutic areas.
Leadership and Structure
Nektar Therapeutics has a leadership team consisting of a CEO, CFO, and other key executives. The company is structured with functional departments responsible for research, development, manufacturing, and commercial operations.
Top Products and Market Share
Key Offerings
- NKTR-255: An IL-15 receptor agonist being developed for oncology applications. This product is still in the clinical trial phase, and has no market share or revenue. Key competitors include companies developing similar IL-15 therapies such as CytoImmune Therapeutics and others in immuno-oncology.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and intense competition. The immuno-oncology field, in particular, is rapidly evolving.
Positioning
Nektar Therapeutics aims to be a leader in developing novel immunotherapies. Their competitive advantage lies in their expertise in polymer conjugation technology and their focus on innovative drug candidates.
Total Addressable Market (TAM)
The total addressable market for immuno-oncology is estimated to be in the tens of billions of dollars annually. Nektar is positioned to capture a portion of this market if their pipeline products are successful.
Upturn SWOT Analysis
Strengths
- Innovative drug delivery technologies
- Experienced management team
- Proprietary pipeline of drug candidates
Weaknesses
- Dependence on clinical trial success
- Limited commercial infrastructure
- History of clinical trial failures
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Advancements in immuno-oncology
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- BMY
- MRK
- PFE
Competitive Landscape
Nektar Therapeutics faces intense competition from established pharmaceutical companies with greater resources and broader product portfolios. Its competitive advantage lies in its innovative technology and focus on specific therapeutic areas.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Nektar Therapeutics's growth has been largely driven by research and development progress and partnerships. However, setbacks in clinical trials have impacted growth.
Future Projections: Future growth depends on the success of their pipeline candidates, particularly NKTR-255. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include focusing resources on core pipeline programs and streamlining operations.
Summary
Nektar Therapeutics is a biopharmaceutical company with innovative drug delivery technologies, but with a history of clinical trial failures. Their success hinges on the progress of their pipeline candidates. The company needs to overcome regulatory hurdles and competition from well-established Pharmaceutical Companies. Analyst ratings are mixed, future is uncertain.
Similar Companies
- BMY
- MRK
- PFE
- LLY
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Financial data is approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nektar Therapeutics
Exchange NASDAQ | Headquaters San Francisco, CA, United States | ||
IPO Launch date 1994-05-03 | CEO, President & Director Mr. Howard W. Robin | ||
Sector Healthcare | Industry Biotechnology | Full time employees 61 | Website https://www.nektar.com |
Full time employees 61 | Website https://www.nektar.com | ||
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.